Florbetapir (F18‐AV‐45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging

Alzheimer's & Dementia - Tập 9 - Trang S72-S83 - 2013
Keith A. Johnson1, Reisa A. Sperling1, Christopher M. Gidicsin2, Jeremy S. Carmasin1, Jacqueline E. Maye2, Ralph E. Coleman3, Eric M. Reiman4, Marwan N. Sabbagh5, Carl H. Sadowsky6, Adam S. Fleisher4,7, P. Murali Doraiswamy3, Alan P. Carpenter8, Christopher M. Clark8, Abhinay D. Joshi8, Ming Lu8, Michel Grundman7,9, Mark A. Mintun8, Michel J. Pontecorvo8, Daniel M. Skovronsky8
1Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA
2Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
3Duke University Medical Center, Durham, NC, USA
4Banner Alzheimer's Institute, Phoenix, AZ, USA
5Banner Sun Health Research Institute, Sun City, AZ, USA
6Nova SE University, Ft. Lauderdale, FL, USA
7University of California San Diego, CA, USA
8Avid Radiopharmaceuticals, Philadelphia, PA, USA
9Global R&D Partners, San Diego, CA, USA

Tóm tắt

ObjectiveTo evaluate the performance characteristics of florbetapir F18 positron emission tomography (PET) in patients with Alzheimer's disease (AD), mild cognitive impairment (MCI), and healthy control subjects (HCs).MethodsFlorbetapir PET was acquired in 184 subjects (45 AD patients, 60 MCI patients, and 79 HCs) within a multicenter phase 2 study. Amyloid burden was assessed visually and quantitatively, and was classified as positive or negative.ResultsFlorbetapir PET was rated visually amyloid positive in 76% of AD patients, 38% of MCI patients, and 14% of HCs. Eighty‐four percent of AD patients, 45% of MCI patients, and 23% of HCs were classified as amyloid positive using a quantitative threshold. Amyloid positivity and mean cortical amyloid burden were associated with age and apolipoprotein E ε4 carrier status.ConclusionsThe data are consistent with expected rates of amyloid positivity among individuals with clinical diagnoses of AD and MCI, and indicate the potential value of florbetapir F18 PET as an adjunct to clinical diagnosis.

Tài liệu tham khảo

10.1016/S0197-4580(97)00062-6 10.1016/S0197-4580(97)00066-3 10.1002/ana.20009 10.1093/brain/awm238 10.1002/ana.21904 10.1001/archneur.64.3.noc60123 10.1001/archneur.64.3.431 10.1093/brain/awn016 10.1016/S1474-4422(10)70043-0 10.1093/brain/awl178 10.1016/j.neurobiolaging.2007.03.029 10.1212/WNL.0b013e3181b23564 10.1002/ana.21598 10.1001/archneur.65.11.1509 10.1002/ana.22333 10.1212/01.wnl.0000326146.60732.d6 10.1016/j.neuron.2009.07.003 10.1097/00007611-199707000-00013 10.1016/j.jalz.2011.03.008 10.1016/S1474-4422(07)70178-3 10.1016/S1474-4422(10)70223-4 10.1016/j.jalz.2011.03.005 10.2967/jnumed.109.065284 10.2967/jnumed.109.069088 10.1001/jama.2010.2008 10.1016/S1474-4422(12)70142-4 10.1212/WNL.34.7.939 10.1016/0022-3956(75)90026-6 10.1097/00002093-199700112-00005 10.1176/ajp.141.11.1356 10.1212/WNL.43.11.2412-a Wechsler D., 1987, Wechsler Memory Scale–Revised Wechsler D., 1981, Wechsler Adult Intelligence Scale–Revised 10.1212/WNL.39.9.1159 10.2967/jnumed.111.090340 10.1016/j.neurobiolaging.2012.06.014 10.1212/WNL.45.11.1985 10.1111/j.1532-5415.1999.tb02571.x 10.1212/01.WNL.0000152982.47274.9E 10.1097/00005072-199812000-00009 10.1093/jnen/62.11.1087 10.1001/archneur.63.5.665 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X 10.1097/00002093-199601040-00002 10.1212/WNL.55.3.370 10.1016/S1474-4422(11)70077-1 10.1016/j.neurobiolaging.2010.04.007 10.1002/ana.22068 10.1002/ana.21610 10.1001/archneurol.2009.279 10.1001/archneur.65.10.noc80013 10.1007/s00401-009-0583-3 10.1212/WNL.0b013e3182661f74 10.1016/j.neurobiolaging.2012.04.017 10.1093/brain/awp062 10.1073/pnas.0900345106
Thông tin
Thông tin xuất bản

Alzheimer's & Dementia

Tập 9

S72-S83

Thông tin tác giả